Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183

1.

Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.

Maki KC, Dicklin MR, Davidson MH, Doyle RT, Ballantyne CM; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.

Am J Cardiol. 2010 May 15;105(10):1409-12. doi: 10.1016/j.amjcard.2009.12.063. Epub 2010 Mar 30.

PMID:
20451686
2.

Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.

Maki KC, McKenney JM, Reeves MS, Lubin BC, Dicklin MR.

Am J Cardiol. 2008 Aug 15;102(4):429-33. doi: 10.1016/j.amjcard.2008.03.078. Epub 2008 May 22. Erratum in: Am J Cardiol. 2008 Nov 15;102(10):1425.

PMID:
18678300
3.

Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.

Davidson MH, Stein EA, Bays HE, Maki KC, Doyle RT, Shalwitz RA, Ballantyne CM, Ginsberg HN; COMBination of prescription Omega-3 with Simvastatin (COMBOS) Investigators.

Clin Ther. 2007 Jul;29(7):1354-67.

PMID:
17825687
4.

Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.

Vega GL, Ma PT, Cater NB, Filipchuk N, Meguro S, Garcia-Garcia AB, Grundy SM.

Am J Cardiol. 2003 Apr 15;91(8):956-60.

PMID:
12686335
5.

Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.

Fazio S, Guyton JR, Polis AB, Adewale AJ, Tomassini JE, Ryan NW, Tershakovec AM.

Am J Cardiol. 2010 Feb 15;105(4):487-94. doi: 10.1016/j.amjcard.2009.10.001. Epub 2009 Nov 13.

PMID:
20152243
6.

The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.

Bays HE, Maki KC, Doyle RT, Stein E.

Postgrad Med. 2009 Sep;121(5):145-50. doi: 10.3810/pgm.2009.09.2061.

PMID:
19820283
7.

Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.

Roth EM, Bays HE, Forker AD, Maki KC, Carter R, Doyle RT, Stein EA.

J Cardiovasc Pharmacol. 2009 Sep;54(3):196-203. doi: 10.1097/FJC.0b013e3181b0cf71.

PMID:
19597368
8.

Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.

Lewin AJ, Kipnes MS, Meneghini LF, Plotkin DJ, Perevozskaya IT, Shah S, Maccubbin DL, Mitchel YB, Tobert JA; Simvastatin/Thiazolidinedione Study Group.

Clin Ther. 2004 Mar;26(3):379-89.

PMID:
15110130
11.

Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.

Grundy SM, Vega GL, McGovern ME, Tulloch BR, Kendall DM, Fitz-Patrick D, Ganda OP, Rosenson RS, Buse JB, Robertson DD, Sheehan JP; Diabetes Multicenter Research Group.

Arch Intern Med. 2002 Jul 22;162(14):1568-76.

PMID:
12123399
12.
14.

Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).

Bays HE, Dujovne CA, McGovern ME, White TE, Kashyap ML, Hutcheson AG, Crouse JR; ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation.

Am J Cardiol. 2003 Mar 15;91(6):667-72.

PMID:
12633795
15.

Effects of simvastatin (40 and 80 mg/day) in patients with mixed hyperlipidemia.

Stein E, Plotkin D, Bays H, Davidson M, Dujovne C, Korenman S, Stepanavage M, Mercuri M.

Am J Cardiol. 2000 Aug 15;86(4):406-11.

PMID:
10946033
16.

Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).

May HT, Anderson JL, Pearson RR, Jensen JR, Horne BD, Lavasani F, Yannicelli HD, Muhlestein JB.

Am J Cardiol. 2008 Feb 15;101(4):486-9. doi: 10.1016/j.amjcard.2007.09.095. Epub 2007 Dec 26.

PMID:
18312763
17.

A 52-week, multicenter, randomized, parallel-group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the treat-to-target (3T) study.

Olsson AG, Eriksson M, Johnson O, Kjellström T, Lanke J, Larsen ML, Pedersen T, Tikkanen MJ, Wiklund O; 3T Study Investigators.

Clin Ther. 2003 Jan;25(1):119-38.

PMID:
12637115
18.

Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.

Bays HE, Maki KC, McKenney J, Snipes R, Meadowcroft A, Schroyer R, Doyle RT, Stein E.

Curr Med Res Opin. 2010 Apr;26(4):907-15. doi: 10.1185/03007991003645318.

PMID:
20156032
19.
20.

Effects of simvastatin on C-reactive protein in mixed hyperlipidemic and hypertriglyceridemic patients.

Bays HE, Stein EA, Shah AK, Maccubbin DL, Mitchel YB, Mercuri M.

Am J Cardiol. 2002 Nov 1;90(9):942-6.

PMID:
12398959
Items per page

Supplemental Content

Write to the Help Desk